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Background
In 2006 Novo Nordisk decided to invest in building a
pipeline within inflammatory disease management. To
support this strategy the cell culture units had to estab-
lish technology for expression and production of mono-
clonal antibodies in CHO cells. A number of technology
providers at that time offered proven platform processes
for this purpose. It was decided to in-license one of
these technology platforms, the one developed at Lonza
Biologics, and focus research resources on product inno-
vation rather than development of an in-house produc-
tion system. The platform has now been fully
implemented and the work flow optimised and
standardised.
Platform process review
The platform process comprises:
￿ Host cell line/expression system
￿ Medium/feeds (chemically defined – animal derived
component free)
￿ Process parameters
￿ Scale-down model (shake flask, 100 ml working
volume).
The platform process has been applied for cell line
development and antibody production for R&D pur-
poses for five years. During this period 11 monoclonal
antibodies have been transferred from laboratory scale
to pilot plant production. The performance of the pro-
cess platform across projects has been reviewed. The
scope of the review was to compare yields obtained in
the scale down model and yields obtained in the
bioreactor process for all 11 antibodies. Figure 1 shows
the results of the review.
In conclusion the review show that
￿ The cell lines are yielding 1.9 – 4.5 g/l mAb.
￿ The scale down model is predictive for the bioreac-
tor process.
Evaluation of an improvement option
An upgrade of the medium, feeds and process protocols
was offered by Lonza Biologics. A b-version of the latest
process from Lonza has been tested and compared to
the previous version in a study including five cell lines.
The experiments were carried out in 100 ml shaker
flask and the scale down version of the process was
applied. A comparison of the two fed batch procedures
is shown below:
Current version: Version 6
Medium and feeds CD-ACF
Two feed solution
￿ Feed rates based on
○ Viable Cell Density
○ Residual glucose
New version: Version 8
Medium and feeds CD-ACF
Five feed solutions
￿ Feed rates based on
○ Viable Cell Density
○ Residual glucose
○ Time
The results of the study are compiled in table 1.
The comparison of the b-test of improved platform
process and the current process showed:
￿ mAb yields improved 1.3 – 2.4 fold
￿ No change in integrated cell area
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Figure 1 Yields of 11 anitbodies in shake flask and bioreactors.
Table 1 Result of the comparison of the two versions of the fed batch process.
mAb Current version: Version 6 New version: Version 8
ICA*
) Lactate mAb ICA Lactate mAb
10E6 viable cell days/ml mmol/l g/l 10E6 viable cell days/ml mmol/l g/l
C 108 57 3.5 92 28 7.1
D 103 61 2.2 90 29 5.2
E 162 65 5.5 104 17 9.0
H 100 55 3.2 120 25 7.0
J 148 62 3.2 164 21 4.3
*
)ICA: Integrated Cell Area.
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